Next Article in Journal
Chemical Aspects of Gut Metabolism of Flavonoids
Next Article in Special Issue
In Vivo Microdialysis of Endogenous and 13C-labeled TCA Metabolites in Rat Brain: Reversible and Persistent Effects of Mitochondrial Inhibition and Transient Cerebral Ischemia
Previous Article in Journal
Metabolic Perturbations from Step Reduction in Older Persons at Risk for Sarcopenia: Plasma Biomarkers of Abrupt Changes in Physical Activity
Previous Article in Special Issue
Palmitate and Stearate are Increased in the Plasma in a 6-OHDA Model of Parkinson’s Disease
Open AccessReview

Imaging Mass Spectrometry: A New Tool to Assess Molecular Underpinnings of Neurodegeneration

1
Department of Biosciences, Rice University, Houston, TX 77030, USA
2
Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
3
Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, Houston, TX 77030, USA
4
Chemical Imaging Research Core at MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
5
Center for Drug Discovery and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
6
Department of Neuroscience and Program in Developmental Biology, Baylor College of Medicine, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Metabolites 2019, 9(7), 135; https://doi.org/10.3390/metabo9070135
Received: 10 May 2019 / Revised: 19 June 2019 / Accepted: 26 June 2019 / Published: 10 July 2019
(This article belongs to the Special Issue Metabolomics in Neurodegenerative Disease)
Neurodegenerative diseases are prevalent and devastating. While extensive research has been done over the past decades, we are still far from comprehensively understanding what causes neurodegeneration and how we can prevent it or reverse it. Recently, systems biology approaches have led to a holistic examination of the interactions between genome, metabolome, and the environment, in order to shed new light on neurodegenerative pathogenesis. One of the new technologies that has emerged to facilitate such studies is imaging mass spectrometry (IMS). With its ability to map a wide range of small molecules with high spatial resolution, coupled with the ability to quantify them at once, without the need for a priori labeling, IMS has taken center stage in current research efforts in elucidating the role of the metabolome in driving neurodegeneration. IMS has already proven to be effective in investigating the lipidome and the proteome of various neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, Huntington’s, multiple sclerosis, and amyotrophic lateral sclerosis. Here, we review the IMS platform for capturing biological snapshots of the metabolic state to shed more light on the molecular mechanisms of the diseased brain. View Full-Text
Keywords: neurodegeneration; metabolomics; biomarkers; imaging mass spectrometry neurodegeneration; metabolomics; biomarkers; imaging mass spectrometry
Show Figures

Figure 1

MDPI and ACS Style

Chen, K.; Baluya, D.; Tosun, M.; Li, F.; Maletic-Savatic, M. Imaging Mass Spectrometry: A New Tool to Assess Molecular Underpinnings of Neurodegeneration. Metabolites 2019, 9, 135.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop